Synaptic abnormalities are a cardinal feature of Alzheimer's disease (AD) that are known to
arise as the disease progresses. A growing body of evidence suggests that pathological …

Positron emission tomography (PET) uses radioactive tracers and enables the functional
imaging of several metabolic processes, blood flow measurements, regional chemical …

Cholinergic synapses are ubiquitous in the human central nervous system. Their high
density in the thalamus, striatum, limbic system, and neocortex suggest that cholinergic …

Over the past several years, there has been a surge in blood biomarker studies examining
the value of plasma or serum neurofilament light (NfL) as a biomarker of neurodegeneration …

Cardiovascular health interacts with cognitive and mental health in complex ways, yet little is
known about the phenotypic and genetic links of heart-brain systems. We quantified heart …

Introduction The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to
validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI is a multisite …

Currently, enhancement of cholinergic neurotransmission via cholinesterase inhibitors
represents the main available approach to treat cognitive and behavioural symptoms of the …

Scientific evidence collected over the past 4 decades suggests that a loss of cholinergic
innervation in the cerebral cortex of patients with Alzheimer's disease is an early pathogenic …

Abnormalities of the endosomal–lysosomal network (ELN) are a signature feature of
Alzheimer's disease (AD). These include the earliest known cytopathology that is specific to …

Regeneration refers to regrowth of tissue in the central nervous system. It includes
generation of new neurons, glia, myelin, and synapses, as well as the regaining of essential …